Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
38.5 USD | +3.19% | -0.77% | -23.90% |
May. 16 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
May. 16 | Sector Update: Health Care Stocks Ease Thursday Afternoon | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.90% | 5.44B | B+ | ||
+42.79% | 50.93B | B- | ||
-0.49% | 42.12B | B | ||
+49.62% | 42.05B | A | ||
-7.20% | 29.18B | C | ||
+12.82% | 26.02B | B- | ||
-21.80% | 18.9B | B | ||
+7.56% | 13.21B | B+ | ||
+24.21% | 12.17B | B+ | ||
+29.99% | 12.16B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IONS Stock
- Ratings Ionis Pharmaceuticals, Inc.